Trendlines (SGX:42T) shared key updates for December 2024, reflecting significant corporate developments and progress across its portfolio companies.
The company completed its proposed subscription on Dec. 5, 2024, and dissolved the Bayer Trendlines Ag Innovation Fund on Dec. 16, 2024. On Jan. 2, it disclosed an investigation into suspected fund misappropriation at a Singapore subsidiary.
Portfolio highlights include Celleste Bio raising $4.5 million to scale its cell-cultured cocoa production, ZygoFix performing its first US surgery post-FDA clearance, and Sol-Chip launching a funding round after a successful German pilot cutting energy use by 35%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。